Sona Nanotech is pleased to announce that it has closed its second non-brokered private placement this month with the issuance of 6,575,000 common shares at $0.25 per share with total gross proceeds for the two financings of $3,143,750. Read the full press release here: https://bit.ly/4dhc4FU #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology
Sona Nanotech Inc.
Nanotechnology Research
Dartmouth, Nova Scotia 1,939 followers
Biocompatible Nanoparticle Technology Being Used to Develop Cancer Therapies & Rapid Diagnostics (CSE:SONA | OTC: SNANF)
About us
Sona Nanotech, a nanotechnology Life Sciences company, is developing Targeted Hyperthermia Therapy™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona’s gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (41-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion – thus enabling drugs to reach all tumor compartments more effectively. The size, shape, and surface chemistry of the gold nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Targeted Hyperthermia Therapy promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech’s gold nanorod particles are cetyltrimethylammonium (“CTAB”) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications with an assessment by the Nanotechnology Characterisation Laboratory that detected neither endotoxins nor microbial contamination. It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.
- Website
-
https://www.sonanano.com/
External link for Sona Nanotech Inc.
- Industry
- Nanotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Dartmouth, Nova Scotia
- Type
- Public Company
- Founded
- 2014
- Specialties
- CTAB free Gold Nanorod production, Gold Nanoparticle Development, Gold Nanorods for bio-medical applications, Gold Nanorods for cancer research, Gold Nanorods for drug delivery, Gold nanorods for cell imaging, POC diagnostic applications, Gold Nanorods for lateral flow assays, Medical, Environment, Health, Pharmaceuticals, Biomedical, Military, Diagnostic, Science, Technology, Healthcare, Research, Lateral Flow Assay, and Rapid Antigen Testing
Locations
-
Primary
Get directions
101 Research Drive
Bay 2
Dartmouth, Nova Scotia B2Y 4M9, CA
-
Get directions
1969 Upper Water Street
Suite 2001
Halifax, Nova Scotia B3J 3R7, CA
Employees at Sona Nanotech Inc.
Updates
-
Sona Nanotech Closes Private Placement Financing to Raise $1,500,000 in Gross Proceeds and Announces Additional Financing. Read the full press release here: https://bit.ly/3MTAACh #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology
-
-
Sona Nanotech Inc. is pleased to announce that it plans to raise up to $1,500,000 through a private placement financing of up to 6,000,000 common shares of Sona at a price of $0.25 per Share. Insiders and certain other existing shareholders of Sona may also subscribe for Shares under the Financing. Read the full press release here: https://bit.ly/4d0JAAX #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology
-
-
Sona Nanotech provides a replay of their recent webinar describing their success with preclinical cancer treatment trials. Watch the full CanAm Physician Recruiting Inc. webinar here: https://lnkd.in/eMjRqhQs #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology
-
-
If you missed our investor webinar, you can watch the replay below to learn about the efficacy study results for Sona's Targeted Hyperthermia Therapy (THT) and its potential to revolutionize cancer treatment. CEO, David Regan, CMO Dr. carman giacomantonio, and CSO Len Pagliaro discussed the recent results from Sona’s preclinical melanoma studies as well as how a vaccine-like effect was achieved. Watch the full webinar replay here: https://lnkd.in/efADjCnZ #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology
-
-
Learn how Sona’s THT therapy achieved a vaccine effect, inhibiting the growth of secondary melanoma tumors in their preclinical efficacy study by joining us for a webinar today at 3 pm EDT for a discussion about Sona’s melanoma data from its current preclinical efficacy study of Sona's innovative cancer treatment therapy, Targeted Hyperthermia Therapy (THT). This is your opportunity to discover how Sona's THT therapy, when paired with conventional immunotherapies, could revolutionize certain cancer treatment outcomes. Register here: https://bit.ly/3RClyTW #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology
-
-
Sona observes a 'vaccine effect' in pre-clinical melanoma study in which new tumor growth was inhibited. Beyond shrinking tumors on its own, Sona’s Targeted Hyperthermia Therapy also stimulated innate immune systems to target and inhibit untreated tumors when combined with a standard immunotherapeutic drug, IL-2. The detailed biomarker and gene expression analysis indicates this was achieved via a lasting activation of the innate immune system. Read the full press release here: https://bit.ly/4c8iR4R #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology
-
-
Join CEO, David Regan, CMO Dr carman giacomantonio, and CSO Len Pagliaro for an exclusive webinar tomorrow at 3 pm EDT for a discussion about Sona’s melanoma data from its current preclinical efficacy study of Sona's innovative cancer treatment therapy, Targeted Hyperthermia Therapy (THT). This is your opportunity to discover how Sona's THT therapy, when paired with conventional immunotherapies, could revolutionize certain cancer treatment outcomes. Register here: https://bit.ly/3RClyTW #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology
-
Join CEO, David Regan, CMO Dr carman giacomantonio, and CSO Len Pagliaro for an exclusive webinar on 26 June at 3 pm EDT for a discussion about Sona’s melanoma data from its current preclinical efficacy study of Sona's innovative cancer treatment technology, Targeted Hyperthermia Therapy (THT). This is your opportunity to discover how Sona's THT technology, when paired with conventional immunotherapies, could revolutionize certain cancer treatment outcomes. Register here: https://bit.ly/3RClyTW #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology
-
-
Sona Nanotech Inc. is pleased to announce that its targeted hyperthermia therapy demonstrated positive results with a second cancer type in its preclinical efficacy study. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona’s THT achieved responses in a preclinical melanoma model similar to those from its recently reported triple negative breast cancer study. Read the full news release here: https://bit.ly/4c8n9cx #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology